Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2016-07-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The place of opioid system in anorexia nervosa (AN) physiopathology is still unclear. Conflicting results were published on cerebral spinal fluid or peripheral levels in anorexia nervosa. However, no data have been reported on opioid cerebral activity. Diprenorphine is a ligand with non-selective binding to opiate receptors µ, κ and δ capable to assess the interaction between endogenous opioids and their receptors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa

NCT00670293

Eating Disorders

COMPLETED

PET Imaging Study of Recovered Anorexics

NCT00603018

Anorexia Nervosa

COMPLETED NA

Anorexia Nervosa and Its Effects on Brain Function, Body Metabolism and Their Interaction

NCT05101538

Anorexia Nervosa

COMPLETED

Serotonin Role on Brain Circuits Involved in Food Avoidance in Anorexia Nervosa

NCT05155280

Anorexia Nervosa

TERMINATED NA

Naltrexone Neuroimaging in Teens With Eating Disorders

NCT05509257

Eating Disorders Binge Eating Purging (Eating Disorders) +2 more

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Body Dysmorphic Disorders Anorexia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

anorexia nervosa patients

Cerebral \[11C\]diprenorphine Binding Potential measured by Positron emission Tomography (PET)

Group Type EXPERIMENTAL

Positron Emission Tomography using [11C]diprenorphine

Intervention Type DRUG

PET using \[11C\]diprenorphine

Recovered anorexia nervosa patients

Cerebral \[11C\]diprenorphine Binding Potential measured by Positron emission Tomography (PET)

Group Type EXPERIMENTAL

Positron Emission Tomography using [11C]diprenorphine

Intervention Type DRUG

PET using \[11C\]diprenorphine

Healthy Volonteers

Cerebral \[11C\]diprenorphine Binding Potential measured by Positron emission Tomography (PET)

Group Type EXPERIMENTAL

Positron Emission Tomography using [11C]diprenorphine

Intervention Type DRUG

PET using \[11C\]diprenorphine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Positron Emission Tomography using [11C]diprenorphine

PET using \[11C\]diprenorphine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PET

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AN patients DSM IV criteria including amenorrhea BMI \< 17.5 kg/m² and abnormal nutritional markers Group 1 (N=15) : long period of / recurrent weight loss (\> 2 yrs) Group 2 (N=15) : recent weight loss (6 to 12 months)
* Recovered AN patients History of AN Weight recovery and BMI \> 18.5 kg/m², stable for at least 12 months Normal nutritional markers Group 1 (N=15) : menses recovery after bodyweight stabilization Group 2 (N=15) : long persistence of amenorrhea (\> 12 months) despite weight recovery
* Healthy volunteers (N=15) BMI between 18.5 and 25 kg/m², normal nutritional markers, absence of psychiatric or organic pathology
* For all subjects Women 18-35 yrs Written and sign consent Affiliation to health insurance

Exclusion Criteria

* History of heart failure
* Psychotropic treatment , antiepileptics
* Ongoing or suspected pregnancy, positive beta HCG test before brain imaging
* Intense physical activity
* Constrains for MRI (ferromagnetic implants or claustrophobia)
* Refusal to be informed in case of incidentaloma revealed by brain imaging
* Refusal for written consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes